← All trials
NCT02374645
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2015
- Primary completion
- Nov 28, 2017
- Completion date
- Apr 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Hutchison MediPharmaLead sponsor
- Shantou UniversityOverall official - principal investigator
- AstraZenecaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.